Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients.
Molecular targeted therapies are becoming ubiquitous in cancer treatment. These drugs may cause gastrointestinal toxicities including perforation, pneumatosis, enteritis, colitis and fistula formation. Knowledge of these complications and their management enables early radiological identification and appropriate intervention, reducing patient morbidity and mortality.
Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA.
E
E
Thornton
S A
SA
Howard
J
J
Jagannathan
K M
KM
Krajewski
A B
AB
Shinagare
K
K
O'Regan
J M
JM
Cleary
N H
NH
Ramaiya
D000368:Aged; D003092:Colitis / Q000000981:diagnostic imaging / Q000209:etiology; D005260:Female; D005759:Gastroenteritis / Q000000981:diagnostic imaging / Q000209:etiology; D006801:Humans; D007410:Intestinal Diseases / Q000000981:diagnostic imaging / Q000209:etiology*; D007412:Intestinal Fistula / Q000000981:diagnostic imaging / Q000209:etiology; D007416:Intestinal Perforation / Q000000981:diagnostic imaging / Q000209:etiology; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000628:therapy*; D011006:Pneumatosis Cystoides Intestinalis / Q000000981:diagnostic imaging / Q000209:etiology; D014057:Tomography, X-Ray Computed